Hexima Ltd (AU:HXL)
ASX:HXL
Top Page
Hexima Ltd
(Sydney:HXL)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.01
▲(20.00% Upside)
Action:ReiteratedDate:12/30/25
The score is primarily driven by weak financial performance—recurring losses, negative cash flow, and revenue falling to near-zero—partially offset by a low-debt balance sheet. Technicals show some upward bias versus moving averages but with extreme/erratic momentum signals, while valuation is pressured by a negative P/E and no dividend support.
Positive Factors
Conservative Leverage
A low-debt balance sheet reduces financial risk and refinancing pressure, providing stability and flexibility in strategic planning.
Negative Factors
Revenue Volatility
Extreme revenue volatility and near-zero levels indicate weak commercialization, posing challenges to achieving sustainable growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Leverage
A low-debt balance sheet reduces financial risk and refinancing pressure, providing stability and flexibility in strategic planning.
Read all positive factors
Hexima Ltd (HXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.17M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-3.47
Revenue GrowthN/A
EPS Growth46.43%
CountryAU
EmployeesN/A
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding167,039,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hexima Ltd Business Overview & Revenue Model
Company Description
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase...
How the Company Makes Money
Hexima Ltd generates revenue through the commercialization of its proprietary plant-derived protein technologies. The company's key revenue streams include the sale of licensed products to agricultural producers and pharmaceutical companies, as we...
Hexima Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.48M | 5.81M | 4.08M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.47M | 5.67M | 3.93M |
| EBITDA | 0.00 | 0.00 | -995.54K | -3.08M | -15.21M | -10.34M |
| Net Income | -503.83K | -503.83K | -933.87K | -1.92M | -10.02M | -6.87M |
Balance Sheet | ||||||
| Total Assets | 1.56M | 1.56M | 2.27M | 2.96M | 10.75M | 8.58M |
| Cash, Cash Equivalents and Short-Term Investments | 1.54M | 1.54M | 2.23M | 2.19M | 3.96M | 3.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 32.00K |
| Total Liabilities | 40.70K | 40.70K | 248.67K | 174.45K | 6.19M | 5.53M |
| Stockholders Equity | 1.52M | 1.52M | 2.02M | 2.78M | 4.57M | 3.05M |
Cash Flow | ||||||
| Free Cash Flow | -637.19K | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Operating Cash Flow | -637.19K | -637.19K | -161.90K | -1.76M | -9.76M | -5.79M |
| Investing Cash Flow | 46.79K | 46.79K | 98.00K | 38.97K | -1.80K | -903.00 |
| Financing Cash Flow | -100.00K | -100.00K | 100.00K | -3.66K | 10.34M | 7.90M |
Hexima Ltd Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Neutral
100.00
Negative
-150.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HXL, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -150.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HXL.
Hexima Ltd Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
53 Neutral | AU$29.39M | -2.50 | -370.40% | ― | 306.88% | ― | |
47 Neutral | AU$8.02M | -3.28 | 265.12% | ― | ― | 24.09% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
42 Neutral | AU$9.43M | -1.00 | -218.76% | ― | ― | ― | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% |
* Financial Sector Average
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:VBS
Vectus Biosystems Limited
0.15
0.07
87.50%
AU:CMB
Regeneus Ltd.
0.35
0.06
23.21%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
Hexima Ltd Corporate Events
Hexima Ltd Announces Successful AGM Results
Nov 27, 2025
Hexima Ltd announced the results of its 2025 Annual General Meeting, where all resolutions, including the remuneration report and the re-election of Mr. Phillip Hains, were passed by a poll. The successful passing of these resolutions indicates st...
Hexima Ltd Outlines Future Amidst Clinical Setbacks
Nov 27, 2025
Hexima Ltd’s Chair addressed the company’s current position and future direction at the 2025 Annual General Meeting. After disappointing clinical trial results for its onychomycosis treatment, Hexima has shifted focus, transferring int...
Hexima Limited Explores Strategic Opportunities Amid Quarterly Financial Update
Oct 31, 2025
Hexima Limited reported a cash balance of $1.44 million for the quarter ending September 30, 2025, with net cash usage of $95,000 in operating activities. The company is exploring strategic opportunities, including a potential capital return to sh...
Hexima Limited Announces 2025 AGM Details
Oct 24, 2025
Hexima Limited, listed on the ASX under the ticker HXL, has announced the details of its upcoming 2025 Annual General Meeting (AGM). The meeting is scheduled to take place on November 27, 2025, at the offices of QR Lawyers in Melbourne, Australia....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.